Hepatocellular carcinoma in the setting of Interferon-free treatment for chronic HCV hepatitis - experience of a single center

Iliescu, Elena Laura; Mercan-Stanciu, Adriana; Toma, Letiția; Ioaniţescu, Simona; Radu, Dumitru; Rusie, Daniel

doi:10.20517/2394-5079.2017.48

Cited by 4 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, patients presented an infiltrative type HCC, difficult to observe on abdominal ultrasonography or even CT scan, requiring MRI. [99] In a multicenter trial in Brazil, out of 222 patients with advanced fibrosis, one patient was diagnosed with HCC at the end of therapy, despite initial screening, was not evaluated for SVR and subsequently died. [100]…”

Section: Obv/ptv/r + Dsvmentioning

confidence: 99%

Hepatocellular Carcinoma and Antiviral Therapies in HCV Chronic Infection

Iliescu¹

2021

Advances in Hepatology

View full text Add to dashboard Cite

The development of direct-acting antiviral (DAA) therapies in chronic HCV infection has been associated with increased expectations regarding the prognosis of this infection in the medical community, as the possibility of HCV eradication is now in sight. While the cure of the HVC infection has been associated with a dramatic decrease in its systemic complications, the impact on the progression of the liver disease, especially in patients with cirrhosis, is still controversial. Furthermore, the risk of developing hepatocellular carcinoma (HCC) after direct-acting antiviral therapy is debatable, with studies presenting an increased prevalence of HCC early after the introduction of these therapies, as well as newer contradicting studies. This chapter aims to examine the current literature data available regarding the impact of new HCV therapies in the incidence and prognosis of hepatocellular carcinoma.

show abstract

Section: Obv/ptv/r + Dsvmentioning

confidence: 99%

Hepatocellular Carcinoma and Antiviral Therapies in HCV Chronic Infection

Iliescu¹

2021

Advances in Hepatology

View full text Add to dashboard Cite

show abstract

“…The authors question the clarity of the post-transplant interferon-free treatment guidelines, as the drug interactions between antiviral therapy and immunosuppressants can put the patient at risk but are still the “weapon of choice” for both transplanted or waiting-listed patients with hepatitis C [ 16 ]. There are, however, controversial data regarding the risk of developing hepatocellular carcinoma (HCC) in patients receiving DAAs as a singular treatment, without a liver transplant, for hepatitis C [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Machine Learning Model Validated to Predict Outcomes of Liver Transplantation Recipients with Hepatitis C: The Romanian National Transplant Agency Cohort Experience

Zabara

Popescu

Burlacu

et al. 2023

Sensors

View full text Add to dashboard Cite

Background and Objectives: In the early period after liver transplantation, patients are exposed to a high rate of complications and several scores are currently available to predict adverse postoperative outcomes. However, an ideal, universally accepted and validated score to predict adverse events in liver transplant recipients with hepatitis C is lacking. Therefore, we aimed to establish and validate a machine learning (ML) model to predict short-term outcomes of hepatitis C patients who underwent liver transplantation. Materials and Methods: We conducted a retrospective observational two-center cohort study involving hepatitis C patients who underwent liver transplantation. Based on clinical and laboratory parameters, the dataset was used to train a deep-learning model for predicting short-term postoperative complications (within one month following liver transplantation). Adverse events prediction in the postoperative setting was the primary study outcome. Results: A total of 90 liver transplant recipients with hepatitis C were enrolled in the present study, 80 patients in the training cohort and ten in the validation cohort, respectively. The age range of the participants was 12–68 years, 51 (56,7%) were male, and 39 (43.3%) were female. Throughout the 85 training epochs, the model achieved a very good performance, with the accuracy ranging between 99.76% and 100%. After testing the model on the validation set, the deep-learning classifier confirmed the performance in predicting postoperative complications, achieving an accuracy of 100% on unseen data. Conclusions: We successfully developed a ML model to predict postoperative complications following liver transplantation in hepatitis C patients. The model demonstrated an excellent performance for accurate adverse event prediction. Consequently, the present study constitutes the foundation for careful and non-invasive identification of high-risk patients who might benefit from a more intensive postoperative monitoring strategy.

show abstract

“…Liver cirrhosis (LC) and hepatocellular carcinoma (HCC) are wellknown com plications related to chronic hepatitis C (CHC) infection. 1) Accurate incidence of chronic HCV infection in Egyptian children is not properly known. 2) Transmission of HCV differs in different areas of the world.…”

Section: Introductionmentioning

confidence: 99%

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C

Rashed

Khalaf

Kotb³

2020

Clin Exp Pediatr

View full text Add to dashboard Cite

Background: Immunomodulatory properties of interferon (IFN) have been documented. It may induce autoimmune diseases such as autoimmune thyroiditis with hypo- or hyperthyroidism. In addition, it may impair thyroid hormone synthesis through affecting iodide organification in thyroid gland.Purpose: The aim of this study was to describe thyroid function tests disturbances in children with chronic hepatitis C (CHC) receiving pegylated interferon-alpha (PEG IFN-α) plus ribavirin.Methods: Fifty children with CHC virus infection who received combined pegylated interferon-alpha with ribavirin were selected. Other 50 apparently healthy children of matched age and sex (considered as control group) were selected. All children (100) were subject to liver function tests, virological studies, and follow-up of thyroid function test during and after the treatment course.Results: Our study showed that 28% of children received combined PEG IFN-α plus ribavirin showed subclinical hypothyroidism. After 24 weeks treatment with combined therapy of IFN plus ribavirin, the mean level of thyroid stimulating hormone (TSH) was 3.23±88 mU/mL, while TSH was 1.16± 0.77 mU/mL before starting treatment. On the other hand, mean TSH was 1.09±0.92 mU/mL in normal control group.Conclusion: This study revealed an association between subclinical thyroid dysfunction and treatment with IFN-alpha and ribavirin in children. Further studies on larger number of patients and longer follow-up duration are recommended for further confirmation.

show abstract

Hepatocellular carcinoma in the setting of Interferon-free treatment for chronic HCV hepatitis - experience of a single center

Cited by 4 publications

References 20 publications

Hepatocellular Carcinoma and Antiviral Therapies in HCV Chronic Infection

Hepatocellular Carcinoma and Antiviral Therapies in HCV Chronic Infection

Machine Learning Model Validated to Predict Outcomes of Liver Transplantation Recipients with Hepatitis C: The Romanian National Transplant Agency Cohort Experience

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C

Contact Info

Product

Resources

About